Pembrolizumab was associated with high response rates in surgically unresectable advanced desmoplastic melanoma.

In October 2024, Imuldosa received approval from the Food and Drug Administration based on data from the phase 3 Opportuniti study.

Patients with AD treated with dupilumab are at a lower risk for otitis media and surgical intervention than those treated with pimecrolimus.

Nevus-associated and de novo melanoma have distinct risk factor profiles, with variations in seen for high nevus density and high genetic propensity.

The new AAP schedule provides guidance for routine immunization against 18 diseases, including updates for RSV, influenza, and COVID-19 immunization.